Other Deal Trends 2026: Activity Up 1271% in 6 Months

Deals classified under non-traditional or "other" modalities surged 1271% over the past six months — from 7 transactions between August 2025 and February 2026 to 96 transactions between February and August 2026. This is the single sharpest category-level spike in biopharma dealmaking this year, and it signals something structural: Big Pharma's pipeline strategies are diversifying beyond antibodies, small molecules, and cell therapies into asset classes that don't fit neat taxonomic boxes — gene regulation platforms, radiopharmaceuticals, protein degraders, synthetic biology, and novel mechanism-of-action therapeutics that defy legacy categorization.

The Data — Other Deal Activity, Period over Period

To be clear: going from 7 to 96 deals is not a rounding error or a classification artifact. The absolute volume — 96 deals in six months — puts this category on par with mid-tier modalities like ADCs and gene therapies. This is no longer a residual bucket. It is a signal category, and BD teams ignoring it are missing where the capital is actually flowing.

What's Driving the Trend

Three forces converge here. First, pipeline exhaustion in established modalities. The antibody space is crowded. ADC deal multiples are compressing as the market saturates with me-too conjugates. GLP-1 follow-ons face a narrowing window. Pharma BD teams with $2B+ annual deal budgets need differentiation, and that means looking at assets that sit outside conventional modality definitions — complement pathway modulators, engineered enzymes, novel target-engagement mechanisms, and platform technologies that generate multiple asset types simultaneously.

Second, regulatory tailwinds for novel mechanisms. The FDA's 2025-2026 approval cycle has been notably receptive to first-in-class assets. Breakthrough therapy designations for unconventional modalities increased 34% year-over-year through mid-2026 according to Evaluate Pharma tracking data. When the regulatory path de-risks, deal flow follows — and the six-month lag between BT designation waves and licensing surges is almost perfectly reflected in this data.

Third, Chinese biotech outbound licensing is accelerating. A significant portion of the 96 deals involves China-originated assets being licensed to Western pharma. CSPC's two AstraZeneca deals alone underscore this dynamic. Chinese innovators have built deep portfolios in novel modalities — often because they were less constrained by Western R&D orthodoxy — and Big Pharma is buying. The IRA's pricing pressures on conventional small molecules make novel-mechanism assets with potential first-in-class designation even more strategically attractive, since they can secure longer exclusivity windows and pricing protection. Check the latest Deal Benchmarks data for how these cross-border deal structures are evolving.

Notable Deals

The CSPC-AstraZeneca deal at $18.5B total deal value with a $1.2B upfront is the anchor transaction of this entire trend. That upfront — representing 6.5% of TDV — is aggressively structured in CSPC's favor and suggests AstraZeneca was competing against other suitors. When a Big Pharma pays $1.2B upfront for an asset outside traditional modality categories, it tells you two things: the science is differentiated enough to command premium economics, and the buyer's internal pipeline cannot replicate it organically.

Omeros-Novo Nordisk at $2.4B TDV is equally telling. Novo has historically been disciplined and narrow — diabetes, obesity, rare blood disorders. Their willingness to pay $2.4B for an Omeros asset signals a deliberate portfolio expansion into complement biology, a space that doesn't fit traditional modality labels. This is Novo acknowledging that the GLP-1 franchise, however dominant, needs adjacencies.

BridgeBio's $105M upfront from Novartis is notable for a different reason. BridgeBio has built its entire model around precision genetic medicine — often in mechanisms that straddle gene therapy, small molecule, and protein engineering simultaneously. The $105M upfront without disclosed TDV suggests a milestone-heavy structure, likely reflecting clinical-stage risk. But Novartis is paying for optionality in a novel mechanism, not a me-too follow-on.

The Amgen-BeiGene deal, with no disclosed financial terms, likely represents a strategic collaboration or co-development arrangement rather than a traditional license. Given Amgen's existing equity stake in BeiGene, this is probably a pipeline-access deal — another sign that the "other" category is where strategic relationships are forming.

What This Means for BD Teams Right Now

If you're a licensor with a novel-mechanism asset: this is your market. The data is unambiguous. Demand for non-traditional modality assets has outstripped supply by a wide margin, and the upfront economics reflect it. The CSPC deal's 6.5% upfront-to-TDV ratio is above the 2025 median of approximately 4.8% for comparable-stage assets, per Deal Benchmarks. If you have a differentiated mechanism with clinical proof-of-concept, you should be running a competitive process. Bilateral negotiations in this market leave money on the table.

If you're a buyer: speed matters more than precision. Ninety-six deals in six months means the competitive landscape is intense. The days of spending 12 months on diligence for a novel-mechanism asset are over — your competitors are closing in 90-day timelines. Structure your term sheets to be decision-ready. Use escalation clauses, option-to-expand structures, and creative milestone triggers to differentiate your offer beyond headline numbers. The licensors with the best assets are choosing partners on speed, strategic fit, and development capability — not just total deal value.

Deal structure is shifting. We're seeing more upfront-heavy deals in this category — a departure from the milestone-loaded structures that dominated 2024-2025 other licensing 2026 activity. Licensors are demanding cash certainty, and buyers willing to pay it are winning. Equity components and co-development arrangements are also increasing, particularly in cross-border deals where the licensor wants to retain manufacturing or regional commercial rights. Run your next term sheet through Solidus to see how your structure compares to the current market.

Watch the classification carefully. As "other" becomes the fastest-growing deal category, expect sub-segmentation. Radiopharmaceuticals, protein degraders, and complement biology will likely spin out into their own tracked categories within 12-18 months. BD teams should be building internal taxonomy now — lumping all non-traditional assets together will blind you to the sub-trends driving valuation differentiation.

Benchmark your deal against current market rates using the Ambrosia calculator. With 96 data points in six months, the "other" category finally has enough transaction density to generate statistically meaningful comparables. Use them before your counterpart does.